Nouscom
Chemicals & Related Products · Switzerland · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Bäumleingasse 18, Basel, Basel-City, 405...Phone Number
+41 612011831Website
www.nouscom.comRevenue
$6.3 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Nouscom
Nouscom is a next-generation immunotherapy company focused on developing engineered viral vectored vaccines and oncolytic viruses for cancer treatment. The company utilizes proprietary platforms to create cancer vaccines that encode multiple tumor neoantigens, aiming to enhance the immune response against tumors. With facilities in Basel, Switzerland, and Rome, Italy, Nouscom targets both off-the-shelf and personalized immunotherapies for various cancer types. Their mission is to deliver safe and effective cancer immunotherapies that improve patient outcomes.Explore more
Nouscom Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Nouscom your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Nouscom launches new products
Check out if Nouscom is spiking on competitors!
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Nouscom
Earning: See what the market has to say on Nouscom recently announced quarterly report
Check if Nouscom has recently received funding, and reach out quickly before it becomes old news!
Click to see if Nouscom had a recent Job posting/layoffs
Nouscom, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Nouscom has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Nouscom
Find more new buyers
Company Profile Activity
Activity Insights
Nouscom is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Nouscom is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Nouscom.
Nouscom financials insights
Gather financial insights about Nouscom, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$13.6M
2017
Series B
$46.6M
2024
Series C
$82M
Nouscom Tech Stack
A closer look at the technologies used by Nouscom
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Promotion
Executive Move
Promotion
Executive Move
Executive Moves, Promotion
Funding
Funding
Funding
Nouscom News & Media
Nouscom Highlights Potential of NOUS-209 to Intercept Cancer in Lynch Syndrome Carriers in Seminal Nature Medicine Publication
BASEL, Switzerland – January 16, 2026 – Nouscom, a clinical-stage biotech company developing next-generation immunotherapies to treat cancer at all stages, from early cancer interception to late-stage metastatic disease, today announced that results from its Phase 1b/2 clinical trial of NOUS-209 in Lynch Syndrome (LS) carriers have been published in Nature Medicine (D’Alise et al). Publication of the results in a leading high-impact medical journal marks a key milestone for Nouscom and advancesBRIEF—CMO among Nouscom appointments | Biotechnology | The Pharmaletter
Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vectored immunotherapies, has announced the promotion of SvenNouscom Presents New Positive Phase 1/2b data of NOUS-209 at SITC 2025, Supporting Plans to Initiate Registration-Enabling Study for Cancer Interception in Lynch Syndrome Carriers
Nouscom Presents New Positive Phase 1/2b data of NOUS-209 at SITC 2025, Supporting Plans to Initiate Registration-Enabling Study for Cancer...Nouscom to Present New Positive Phase 1b/2 Clinical and Translational Data on NOUS-209 Immunogenicity and Cancer Interception Potential in Lynch Syndrome Carriers at SITC 2025
Lynch Syndrome (LS) is a common hereditary condition that greatly increases lifetime risk of colorectal, endometrial, urothelial and other...
Read more news
Top Chemicals & Related Products Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Nouscom
Sign Up For FreeTo access detailed company insights
Nouscom is a next-generation immunotherapy company focused on developing engineered viral vectored vaccines and oncolytic viruses for cancer treatment. The company utilizes proprietary platforms to create cancer vaccines that encode multiple tumor neoantigens, aiming to enhance the immune response against tumors. With facilities in Basel, Switzerla... Read More
